Skip to content Skip to sidebar Skip to footer
Home / Medication-assisted Treatment of Opioid Use Disorder Review of the Evidence and Future Directions

Medication-assisted Treatment of Opioid Use Disorder Review of the Evidence and Future Directions

Post a Comment

Opioid use disorder (OUD) is defined by the Diagnostic and Statistical Transmission of Mental Disorders (5th edition)i equally the maladaptive apply of opioids, prescribed or illicit, resulting in two or more criteria that reflect impaired health or part over a 12-calendar month period. OUD is scaled according to severity (balmy/moderate/severe) and does not crave physiological tolerance or dependence in order to exist considered a substance utilize disorder. Text Box ane summarizes core criteria and provides a mnemonic to assistance clinical diagnosis and teaching.

F1-2

In the Us, rates of prescription opioid analgesic misuse rose exponentially in the preceding decade,2 as has the treatment received for both heroin use disorder and opioid analgesic utilise disorder.iii Among persons aged 12 years and older, self-reported lifetime misuse of heroin and opioid analgesics is estimated at well-nigh 2% and 14% of the population, respectively.3

Constructive treatment of OUD has been identified as a national priority to reduce the rates and societal costs of individual inability associated with OUD, the communicable diseases burden associated with intravenous opioid use (particularly hepatitis C [HCV] and HIV transmission), and escalating rates of adventitious opioid overdose deaths and pediatric opioid ingestions.two,four–8 Prior reviews of medication-assisted treatment (MAT) of OUD provide useful guidance to clinicians,9–12 yet algorithms for selecting medication treatment require continuous updating to remain current with the emerging evidence. The goal of this review is to succinctly provide this clinical update and to highlight unresolved challenges in treating OUD.

METHODS

All randomized, controlled trials (RCTs) with English abstracts on medical management of OUD were searched using PubMed mesh terms [opioid dependence OR opioid addiction] AND medication, yielding 502 abstracts. These articles were screened for inclusion as contributing to the show on MAT for OUD. The resulting ready of references was supplemented, based on an examination of abstracts, to include relevant case reports, reviews, meta-analyses, and clinical trials. Finally, the Provider'due south Clinical Back up Organisation for Medication-Assisted Treatment website (www.pcssmat.org), which contains current practice training and educational support for opioid MAT, was reviewed to identify elements of good consensus beyond the current testify.

RESULTS: OVERVIEW OF MAT FOR OUD

Mu-Opioid Receptor Targeted Stabilization of OUD

The Food and Drug Administration (FDA) has approved three medications for preventing opioid relapse and for stabilization/maintenance treatment of OUD: buprenorphine, naltrexone, and methadone. All three are ligands that bind to central mu-opioid receptors as the molecular target for their therapeutic activity, all the same they differ significantly in their respective intrinsic activities at the mu-opioid receptor, their pharmacokinetic and pharmacodynamic properties (with effects on efficacy and toxicity), and the mechanisms by which they confer relapse-prevention protection to treated individuals (Table one).

T1-2
Table 1:

Comparison of FDA-Canonical Medications to Treat Opioid Use Disorder with Physiological Opioid Dependence

In selecting MAT, the first consideration is whether an individual has OUD with physiological dependence. All iii medications are FDA approved based on RCTs demonstrating efficacy and safety in OUD with historical symptoms of physiological dependence (Table 2). The addition of agonist maintenance to relapse-prevention treatment at least doubles the probability, compared to relapse-prevention treatment lonely, that an individual will achieve opioid abstinence during active handling,24–27 and the addition of antagonist maintenance nearly doubles opioid abstinence.23 Oral naltrexone, although FDA approved to treat OUD, is excluded from consideration hither due to poor adherence rates and pregnant opioid-overdose mortality following medication discontinuation in clinical studies of OUD treatment outcomes.28–31 Attempts to pair oral naltrexone with psychosocial interventions aimed at improving compliance and retention in treatment have not notwithstanding demonstrated sustained positive results.29,32 Naltrexone implant and buprenorphine implant are non notwithstanding FDA canonical for OUD, and trials to date provide insufficient evidence of condom and efficacy.33,34

T2-2
Table 2:

Opioid-Abstinence Rates with Medication Compared to Nonmedicationa

The show for efficacy both in reducing opioid utilize and retaining patients in care is strongest for agonist treatment; methadone maintenance remains the gold standard of care for OUD.35 The prove for antagonist treatment of OUD remains comparatively weak, given the bloodshed risk and poor adherence with oral naltrexone, plus the express RCT prove for extended-release naltrexone (naltrexone ER). The latter includes only a trial23 with open-label extensionnineteen in a Russian population without access to agonist therapy and a small trial of employment contingency to meliorate naltrexone ER adherence in a US cohort.36 Also in Russia, a small RCT of employment contingency to improve adherence used a different, non-FDA-approved formulation of naltrexone ER. Efficacy in reducing opioid utilize (60%–lxx% opioid-free urines) was like to the 2 in a higher place trials cited, and the employment-contingency condition improved adherence just did not affect opioid use.37 These studies do not adequately address either safety post-obit medication discontinuation or efficacy compared to agonist therapy, and they pose problems for generalizability. A phase 4, multisite RCT comparing naltrexone ER to buprenorphine/naloxone maintenance is currently under manner, with the expectation that results will resolve safety and efficacy questions regarding naltrexone ER equally a treatment for OUD (NIDA Clinical Trials Network protocol 0051 [Principal Investigator: John Rotrosen/NewYork Academy School of Medicine]; ClinicalTrials.gov identifier NCT02032433).

Unknown Aspects of Mu-Opioid Receptor Functional Activity in MAT

Although it is unremarkably accepted that the functional furnishings of MAT differ co-ordinate to their corresponding intrinsic activities at central mu-opioid receptors, this view is oversimplified. The many complexities of mu-opioid receptor ligand binding and biased agonism (e.g., "functional selectivity" according to mu-opioid receptor/effector coupling and intracellular environment, and agonist-induced receptor conformational changes with prolonged agonist exposure)38–forty are simply now being discovered, and may account for the clinical effects of these medications that remain poorly understood and that announced to vary widely amidst individuals. For instance, little is known about why only sure individuals develop OUD post-obit recurrent opioid exposure, although population studies in patients receiving opioid analgesics place co-occurring substance utilise and mental illness every bit risk factors for developing OUD,41 and a recent meta-analysis suggests that the rs1799971 polymorphism of the OPRM1 gene may confer vulnerability to OUD following exposure to either heroin or prescription opioids.42 Clinically, dosing needs in agonist maintenance therapies different significantly amidst individuals, and most patients practise non develop tolerance to the relapse-prevention efficacy of buprenorphine or methadone maintenance. These observations propose dynamic factors beyond ligand intrinsic activity at mu-opioid receptors. Whistler43 has presented a helpful summary of the converging evidence that opioid agonists having both loftier efficacy and high propensity to produce mu-opioid receptor desensitization and endocytosis ("molecular trafficking") take lower liability for abuse and produce less tolerance than opioid agonists that induce comparatively footling endocytosis. Examples of the erstwhile include endogenous opioid ligands and methadone, whereas the latter include morphine, codeine, buprenorphine,44 and most commonly misused prescription opioids. Thus, endocytosis may help to explicate the lack of tolerance observed for relapse-prevention efficacy with methadone maintenance but would non explain the same observation with buprenorphine maintenance.

Within methadone-maintained patients, pharmacogenomic studies identify variability in treatment response and pharmacokinetics associated with the variants of several genes (OPRM1, ARRB2, KCNJ6, ABCB1) and hepatic CYP450 enzymes, suggesting layers of complexity in any given individual's treatment response.45 For example, a recently published meta-analysis demonstrates that individuals homozygous for the CYP2B6*6 polymorphism are boring metabolizers of both the R- and Due south- enantiomers of methadone and therefore would be expected to have lower dosing requirements.46 The utility of pharmacogenomic screening may be especially important in future clinical practice with methadone maintenance.

Comparison MAT Tolerability and Convenience

RCTs examining methadone, buprenorphine, and extended-release naltrexone injection stabilization are all associated with acceptable adverse-upshot profiles and with an acceptable level of patient tolerance.23–27 Agonist treatment is associated nigh ofttimes with opioid-class furnishings such equally dose-dependent sedation, constipation, sweating, neurocognitive impairment, and sexual dysfunction. Dose-dependent respiratory depression is an agin effect mainly of methadone, a total mu-opioid agonist, whereas the partial-agonist properties of buprenorphine forbid dose-dependent respiratory depression greater than l% reduction of baseline even at Four doses of 2 mcg/kg in opioid-naive healthy volunteers.47 This "ceiling consequence" on respiratory depression has obvious benefits for tolerability as well equally for accidental or intentional overdose. Similarly, buprenorphine'southward partial-agonist properties take a protective "ceiling consequence" that does not induce euphoria in opioid-tolerant individuals, whereas methadone-induced euphoria may be present in the early treatment of OUD only decreases with steady-state dosing stabilization.48

Naltrexone ER is associated about commonly with insomnia, site reactions to injection, clinically insignificant elevation of transaminases, hypertension, nasopharyngitis, and influenza.19,23

Patient convenience for dosing is least burdensome with monthly injections of naltrexone ER or monthly maintenance visits with part-based buprenorphine/naloxone—both modeling typical outpatient handling for severe chronic illness. Dosing is most burdensome with required observed daily dosing in opioid handling programs prescribing methadone or buprenorphine maintenance in the early on phases of recovery.

Retention in Treatment After the Initiation of MAT

All three medications bear witness improved memory in handling compared to placebo or no medication.24–27 Head-to-head comparisons are mainly bachelor for buprenorphine versus methadone maintenance, with methadone demonstrating the highest rates of treatment retention in all studies,35,49 including the treatment of meaning womenfifty and those with HIV.51 Ane RCT conducted in Islamic republic of iran compared all three medications in a cohort of men dependent on intravenous buprenorphine and found that retentiveness in treatment over a 24-week menstruum was best with methadone followed by buprenorphine and then oral naltrexone, although it was noted that the bachelor daily dose of buprenorphine (5 mg) was not an agonist dose equivalent to the study's daily dose of methadone (50 mg)—which likely contributed to poorer retention in the buprenorphine-treated group.52

Impact on HIV Gamble Behaviors

In HIV-infected populations, methadone and buprenorphine maintenance significantly reduce the employ of illicit opioids and the risk of HIV transmission through the use of injection drugs, though their bear upon is less robust on sexual risk behaviors.53–56 In a secondary analysis using a large national cohort from a prophylactic RCT (comparing hepatic responses to 24 weeks methadone and buprenorphine maintenance for OUD),57 an interesting gender difference emerged: sexual risk behaviors increased among men maintained on buprenorphine merely decreased in methadone-maintained men, whereas women decreased run a risk with either buprenorphine or methadone maintenance.51

Impact on Hepatitis C Risk Behaviors

Cumulative, lifetime HCV seroprevalence estimates among injection-drug users is up to 90%,58 with loftier seroconversion rates attributable to both sharing syringes/needles and sharing drug preparation equipment (east.g., drug cookers and spoons, filtration cottons, vehicle fluids).59,60 Two large, prospective cohort studies study the protective effect of methadone61,62 and buprenorphine62 maintenance, but not detoxification, in preventing HCV seroconversion among developed injection-drug users who are HCV negative at treatment entry.

Touch on on Preventing Opioid Overdose

Several risk factors for unintended opioid overdose have been identified. They include misuse of heroin and opioid analgesics, misuse of diverted buprenorphine and methadone, increases in opioid prescribing, having 4 or more prescribers or pharmacies filling opioid prescriptions, being prescribed doses equivalent to more than 100 mg morphine, opioid ingestion coupled with alcohol or the use of other sedatives/hypnotics (with synergistic furnishings on respiratory low), receipt of public subsidy income providing admission to drug purchase and rampage drug use, suboptimal methadone-induction practices in relation to both pain management and addiction, opioid-analgesic switching, previous overdose history, loss of opioid tolerance amid OUD due either to extended abstinence during incarceration or to treatment-related abstinence, and older age, with smoking status and co-occurring medical weather likely contributing to fatalities.2,63–71 Given that MAT reduces illicit opioid use, educates about OUD and accidental-overdose prevention, and may provide (where available) intranasal naloxone rescue kits to family unit and friends for use at the scene of an opioid overdose,68,72 it is expected that MAT would be an important factor in preventing accidental opioid-overdose deaths occurring in those with OUD while they remain in active treatment. While information to date suggest that that is indeed the case for buprenorphine, methadone, and naltrexone ER,19,63 more information are required to judge the rubber of MAT post-obit treatment dropout and planned medication discontinuation, particularly for antagonist therapies for which the preclinical20 and clinical28,31,73 evidence indicates increased risk for respiratory depression upon opioid agonist reexposure.

Safety Contour of MAT

Buprenorphine and methadone57 and naltrexone ER19,74 maintenance have favorable safety profiles, with HCV-infection being the most common predictor of mild-to-moderate increases in transaminases among adults, pregnant women,75 and youth.26,76 Methadone adventure for QTc prolongation (associated with torsades de pointes, which has an estimated 10%–17% run a risk of sudden death due to cardiac arrhythmia77) is dose dependent, only screening baseline QTc intervals has non yet been shown to assist hazard management during methadone maintenance.78 Neither buprenorphine nor naltrexone is associated with QTc prolongation.

Drug-drug interactions are numerous with methadone, due to many cytochrome P450 isoenzymes involved in its hepatic metabolism (mainly CYP3A4, but also CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and CYP2D6).12,xviii Metabolic inhibitors that increase methadone peak concentrations pose a hazard for sedation and respiratory depression, bowel immotility, and QTc prolongation and cardiac arrhythmia; whereas metabolic potentiators that reduce methadone summit and trough concentrations pose a gamble for opioid withdrawal and relapse to opioid use. Other substances and drugs having like agin effects (sedation, reduced bowel motility, QTc prolongation, and reductions in middle rate, blood pressure, and respiratory rate) may pose additive and synergistic effects, even if they do non change methadone metabolism. Mutual examples include alcohol and benzodiazepines (sedation and reduced respiratory drive), antipsychotics, tricyclic antidepressants, and calcium channel blockers (QTc prolongation), and psychotropics with anticholinergic effects (constipation).

Past comparison, buprenorphine and naltrexone have few drug-drug interactions and a benign side-upshot contour. Owing to its partial-agonist properties, buprenorphine is not associated with a meaning take chances for respiratory low;47 nevertheless, in combination with sedatives/hypnotics (especially diazepam),79–81 it poses a risk for sedation and reduced respiratory bulldoze. Naltrexone has no take a chance for reduced respiratory bulldoze, merely attempts to "override" blockade with loftier-dose opioid utilize poses a chance for accidental-overdose decease (come across Vivitrol® package insert). Buprenorphine is metabolized primarily by CYP3A4 and has clinically meaning drug-drug interactions with rifampin (reductions in buprenorphine concentrations pose a risk for opioid withdrawal, although this effect is not observed with rifabutin)82 and atazanavir (increased buprenorphine concentration and sedation/cognitive impairment).83 Buprenorphine has not had confirmed, clinically significant CYP3A4 or CYP2D6 interactions with other commonly prescribed psychotropics and medications, although exceptional instance reports exist; definitive human studies are lacking.xviii,84 Naltrexone is non metabolized by cytochrome P450 isoenzymes; instead, information technology has hepatic metabolism via dihydrodiol dehydrogenase to β-naltrexol, which is then conjugated for urinary excretion.84 Its major drug interaction is occludent of opioid analgesic efficacy.

In pregnancy, naltrexone ER has no demonstrated safety, whereas both buprenorphine and methadone maintenance are safe and effective for maintaining maternal forbearance and retention in prenatal care,85 and are safely recommended during breastfeeding.86,87 Buprenorphine demonstrates less tiptop-dosing suppression of fetal heart rate, fetal eye charge per unit reactivity, and biophysical profile scores, and generates a milder neonatal abstinence syndrome than methadone.88,89 Early neonatal development appears within normal limits for infants exposed to buprenorphine or methadone in utero.xc Longer-term neurodevelopmental safety is known for infants exposed in utero to methadone91 and is being investigated for buprenorphine-exposed infants.

Ease of Induction and Comparison of Available MAT Formulary

The MAT formulary available in the U.s.a. for treating OUD is summarized in Table three. Naltrexone ER is available just under a brand name, whereas buprenorphine monotherapy, buprenorphine/naloxone, and methadone are all available both generically and under brand names. Oral methadone concentrates are dose-equivalent, but the differences in formulations for buprenorphine/naloxone are non reliably dose-equivalent (come across, e.g., the dosing differences with buccal film). Converting betwixt these forms of buprenorphine/naloxone requires careful attention to dosing practices (nutrient and smoking should be avoided xxx minutes before and after dosing, and dissolved medication should be held with saliva for a full 10 minutes to optimize mucosal absorption) and to patient response. Full general dosing ranges for both induction and for stabilization/maintenance treatment are too listed in Table 3.

T3-2
Table three:

Opioid Use Disorder Formulary in the United States

An reward of methadone is that it tin can be started at any time during an overarching form of treatment. A disadvantage, however, is that it takes time to accomplish a steady-country dose that is therapeutically effective in OUD, and this time period is one of high risk for treatment dropout and accidental overdose if titration is as well rapid.17,92 Buprenorphine requires the individual to be in mild-moderate opioid withdrawal prior to dosing, in gild to avoid precipitating severe opioid withdrawal (due to its partial-agonist activity), only relief is accomplished within 24–72 hours of consecration for both monotherapy and the naloxone-combined product. The fractional-agonist "ceiling effect" protects against respiratory depression, thus rendering this medication safe for rapid induction. Buprenorphine monotherapy is recommended for observed induction and for stabilizing or maintaining pregnant women or those that may respond adversely to naloxone due to allergies or co-occurring medical conditions. The combination product is buprenorphine plus naloxone in a four:1 ratio and was designed to foreclose misuse and diversion of buprenorphine amongst injection drug users. Buprenorphine has practiced bioavailability via oral mucosal absorption, whereas naloxone does not. Taken sublingually, the naloxone component has poor bioavailability, just if crushed and injected, the naloxone component is readily available to exert opioid antagonist effects, thus reducing the risk of abuse in buprenorphine treatment. Buprenorphine/naloxone is consequently the formula of pick for inductions that are not fully observed and for routine maintenance, in order to reduce product diversion and misuse. Naltrexone ER has the most complicated induction profile because of the need to complete metabolism of opioid agonists prior to dosing (typically seven–14 days), thereby avoiding astringent opioid withdrawal (due to its antagonist activity). Prolonged symptoms of opioid withdrawal during washout pose a high risk for treatment dropout and relapse. Attempts to abbreviate this period require more complex dosing algorithms as well every bit dorsum-upward options for environmental containment to preclude relapse to opioid use.93

Risk for Diversion and Negative Public Health Impact

Buprenorphine (all formulations) and methadone are known to be diverted by patients and to exist commonly used illicitly,63,94,95 resulting in further opioid misuse and overdoses, in accidental pediatric exposures,96 and in accidental or intentional adolescent exposures.6 Since naltrexone ER has no known diversion value, it allows for the treatment of OUD without contributing to illicit opioid use.

DISCUSSION

Factors to Consider in Selecting Treatment with MAT

MAT is recommended for adults presenting for clinical handling of OUD with physiological dependence: information technology significantly augments treatment retentivity, reduces illicit opioid use, reduces the brunt of opioid peckish, and, in the case of agonist therapies, provides effective relief of the opioid withdrawal syndrome. Thus, MAT is a stabilizing addition to relapse-prevention counseling and mutual help groups (such as Narcotics Anonymous) in that it increases the effectiveness of those interventions. Longer-term, abstinence-based residential treatment without MAT shows express effectiveness, especially among recently detoxified heroin users,97,98 and loss of tolerance during this period of abstention poses an increased risk of fatal overdose if one relapses to opioid use upon belch to home. Youth is a predictor of early dropout from psychosocial treatment of OUD,99 whereas medication adherence and early opioid forbearance predict greater retention and treatment success among youth treated with buprenorphine/naloxone.100 A 2005 Cochrane review noted that the available evidence was bereft to back up psychosocial treatment alone as constructive for OUD.101 The evidence remains bereft, even to predict which individuals, if whatsoever, are probable to practice well without MAT.

The option of MAT can be viewed from ii different perspectives: individualized treatment versus population management. An individualized treatment arroyo will consider many factors, in add-on to the prove base of operations, to guide medical decisions. These factors include the post-obit: the availability of, and patient'southward access to, MAT; the experience of the prescribing clinician; the clinical setting of treatment; patient and family preferences; occupational risks (see next paragraph); co-occurring medical and psychiatric illnesses; and the patient's motivation for opioid forbearance, capacity to attach to recommended treatment, and legal status. If the risk for treatment dropout is loftier, the testify regarding MAT and retention in treatment significantly favors a recommendation for agonist therapy; methadone maintenance demonstrates the highest patient retention rates in all studies comparing methadone to buprenorphine. A recommendation of methadone or buprenorphine/naloxone maintenance must also be balanced by a give-and-take with the patient (including informed consent) regarding both the difficulty of terminating agonist therapies (due to reexperiencing opioid withdrawal and craving) and the loftier rates of opioid relapse following the discontinuation of either buprenorphine25,26 or methadone.102,103 Unfortunately, no long-term studies accept compared taper outcomes with buprenorphine versus methadone. Clinicians are encouraged to monitor taper trials closely for whatsoever evidence of patient destabilization or relapse risk that would require returning to higher-dose agonist treatment. The benefits of extended methadone or buprenorphine/naloxone maintenance delivered within an opioid treatment plan (requiring daily medication monitoring during early on recovery, and providing structured psychosocial interventions and integrated intendance options) are specially pronounced for populations with significant drug-related legal charges and drug-using social networks, for patients with co-occurring medical illness related to injection drug utilise, and for socially disadvantaged patients, who may receive, through the integrated structure of the programme, the intensive social and medical services needed to support sustained recovery.

In some situations, the selection of MAT may reflect adventure-do good assessments unrelated to the medical factors as such. For instance, the performance of pilots, physicians, professional athletes, or those carrying firearms could be compromised and even exist unsafe because of opioid agonist treatment's cognitive or allaying effects or its impact on reaction times.104,105 No studies specific to these professions take been conducted for agonist therapy of OUD, even so, so this business organization is empirical rather than evidence based at this time. In such cases, antagonist therapy may be preferred for a motivated, handling-seeking individual who desires to go on such employment, despite the comparatively weak evidence supporting antagonist versus agonist therapies. Similarly, an individual with co-occurring OUD and booze employ disorder might benefit most from adversary therapy, given that the FDA has canonical naltrexone ER as constructive in preventing relapse to alcohol use.106,107 In all such situations, these matters should be covered in a collaborative informed consent process, and clinicians should carefully document the give-and-take.

A population-management approach would consider the public health touch of OUD, forth with the cost-effectiveness of the available treatment options, over patient preferences and individualized selection of MAT. Primary consideration would be given to preventing opioid diversion into the customs, opioid overdose deaths, and the manual of infectious diseases (in particular, hepatitis C and HIV) through the utilize of injection opioids. To optimize such decisions, all three MAT options for OUD would need to exist available, and prescribers would need to be trained in the advisable use of each one. Lack of prescriber familiarity and condolement with MAT, as well equally limits imposed on prescribers by managed care (east.one thousand., dosing limits, prior authorization reviews, and limits on toxicology), continue to exist barriers to dissemination of MAT for OUD in clinical practice.108 The availability of a regularly updated, evidence-based algorithm to assist in decision making would likewise contribute to the adoption of MAT in exercise.109

An example of a simple, prove-based algorithm for MAT selection—ane designed to be flexible in relation to regional MAT availability—is outlined in Text Box two. Failed treatment trials would result in the selection of an alternate MAT treatment or in the relocation of treatment itself—for instance, from an office to a structured treatment setting with closer patient monitoring, such as an opioid handling program, an integrated mental health intendance clinic, or a specialized integrated care dispensary (post-obit an integrated care model as is used for infectious diseases). In the United States, methadone maintenance must currently be delivered inside a federally regulated opioid treatment program, but some evidence suggests, as a future pick, that methadone maintenance can be effectively delivered inside an office-based setting, especially for clinically stable patients who have achieved take-home doses.110–112 The use and implementation of a MAT algorithm would reduce discrepancies in treatment based on regional variations, prescriber expertise, or access to specialty clinics. The main weakness of this approach, nonetheless, is that it could reduce the part of patient preferences in selecting MAT. This consideration is a serious i in framing an effective population-management approach since patient date in substance utilize handling is essential for optimal outcomes. Service-utilization research and feedback from programs using this approach are much needed.

F2-2

MAT Selection in Adolescents

The buprenorphine/naloxone combination is FDA approved for adolescents aged 16 and older and has demonstrated condom and efficacy for youth with OUD.26 As such, it is currently the treatment of selection. Nevertheless, business organization about adolescent nonadherence and the misuse and diversion of buprenorphine/naloxone has generated some support for empirical treatment with naltrexone ER. Caution is advised, notwithstanding, because show is lacking equally to the safety and efficacy of naltrexone ER in this population. In the Usa, methadone maintenance is not available for the treatment of adolescents.

MAT Choice in Women of Childbearing Age

For women of childbearing historic period and those who are pregnant or planning pregnancy, careful word, along with informed consent, is required in selecting MAT. Although methadone maintenance is the current golden standard of clinical care during pregnancy, buprenorphine monotherapy (but non buprenorphine/naloxone, though early evidence suggests that the combination warrants further study)113 is a potential alternative based on studies comparing the safety and efficacy of these treatments during pregnancy.85 Postpartum breastfeeding mothers may exist switched from buprenorphine monotherapy to combination buprenorphine/naloxone maintenance in order to prevent diversion, peculiarly since naloxone is poorly absorbed sublingually and is unlikely to be absorbed by suckling infants.114

Lack of Clinical Studies for Using MAT in Nondependent OUD

No research has examined MAT in nondependent OUD, and fifty-fifty case reports are lacking on this topic. Such off-label use, which would require advisable informed consent and risk-direction consultation, should not be considered without careful deliberation and documentation of medical decision making. Theoretically, OUD without whatever history of physiological dependence would favor antagonist treatment in nigh cases, as maintenance on agonist therapy will induce physiological opioid dependence. In most cases, this risk would not exist perceived to outweigh benefit except in the presence of an imminent take chances of death by opioid overdose. Such situations include recurrent or recent most-fatal overdoses with opioids or a recent intentional opioid overdose in an impulsive individual returning to an outpatient setting. In these examples, the preserved or augmented opioid tolerance provided past agonist treatment might be considered protective against future toxic opioid use, in which case buprenorphine/naloxone would be favored over methadone because of its lower hazard of opioid toxicity and fewer drug-drug interactions. Another example may be the patient with a co-occurring pain syndrome who requires intermittent opioid analgesia, satisfies criteria for OUD without physiological dependence, but misuses opioid analgesics. In this example, depression-dose buprenorphine/naloxone maintenance in a divided-dosing regimen could potentially enable pain treatment and circumvent opioid misuse; indeed, studies of OUD with physiological dependence testify buprenorphine/naloxone to provide a do good in mild-to-moderate pain syndromes.25,115 Note, notwithstanding, that the in a higher place comments reflect theoretical considerations only; bear witness for efficacy and safe is lacking for all three medications in relation to nondependent OUD.

Need for Development of Non-opioid Therapies to Meliorate Acute and Protracted Opioid Withdrawal Syndromes

Opioid withdrawal is commonly misrepresented equally a "influenza-like" syndrome due to the constellation of physical symptoms characterizing acute hyperadrenergic rebound, along with malaise and gastrointestinal distress. This concept of opioid withdrawal is incomplete, however, in that it ignores the astringent affective and cognitive distress (including treatment-resistant anxiety, dysphoria/low, severe opioid peckish, and loss of self-efficacy) that persists up to 30 days in untreated OUD abstinence116,117 and that contributes to opioid relapse and treatment dropout, fifty-fifty among young OUD patients with relatively brief histories of dependence.118

Potential non-opioid treatments to stabilize opioid withdrawal and opioid craving may be developed through an understanding of how neurobiological circuitry interacts with opioid pathways.119 Such treatments would be expected to relieve symptoms, improve retention in care, ease induction, and possibly increase the options for managing OUD during pregnancy. A pocket-size pilot RCT (n = 24) of buprenorphine detoxification with and without gabapentin, a GABAergic anticonvulsant, demonstrated better short-term opioid-use outcomes with gabapentin,120 but two RCTs assessing the apply of memantine, a glutamatergic adversary, as an adjunct to naltrexone ER induction and stabilization121 or to oral naltrexone122 had negative results. Further research on novel pharmacotherapies to ease opioid withdrawal are warranted.123,124

Clinicians are encouraged to educate patients near opioid withdrawal and its presenting a gamble for opioid relapse and for dropping out of treatment. A collaborative program should exist adult, in accelerate, for managing opioid withdrawal. For example, informed consent with agonist therapies should include a discussion both of opioid withdrawal as presenting a risk for relapse and of the future inevitability of experiencing opioid withdrawal when discontinuing agonist handling or if doses are missed. Collaborative handling plans that include aggressive pharmacological direction of symptom relief and options for safety containment in higher levels of care (such as fractional or residential treatment programs) would be expected to improve retentiveness in intendance and, more than generally, the patient's agreement of how to avoid relapse to opioid use.

Declaration of interest

The writer reports no conflicts of interest. The author alone is responsible for the content and writing of this article.

REFERENCES

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: APA, 2013.

  • Cited Hither

two. Centers for Illness Command and Prevention. Vital signs: overdoses of prescription opioid hurting relievers—United States, 1999–2008. MMWR Morb Mortal Wkly Rep 2011: 60: 1487–92.

  • Cited Hither

3. Substance Abuse and Mental Wellness Services Administration. Results from the 2012 National Survey on Drug Use and Health: summary of national findings. Rockville, MD: SAMHSA, 2013. http://world wide web.samhsa.gov/data/sites/default/files/NSDUHnationalfindingresults2012/NSDUHnationalfindingresults2012/NSDUHresults2012.pdf

  • Cited Here

4. Executive Role of the President of the United States. Epidemic: responding to America's prescription drug corruption crisis. 2011. http://publications.iowa.gov/12965/1/NationalRxAbusePlan2011.pdf

  • Cited Here

5. Bailey JE, Campagna E, Dart RC; RADARS Organisation Poison Center Investigators. The underrecognized toll of prescription opioid corruption on young children. Ann Emerg Med 2009; 53: 419–24.

half dozen. Zosel A, Bartelson BB, Bailey East, Lowenstein South, Dart R. Characterization of adolescent prescription drug abuse and misuse using the Researched Abuse Diversion and Addiction-related Surveillance (RADARS(®)) Organization. J Am Acad Child Adolesc Psychiatry 2013; 52: 196–204.

7. Valdiserri R, Khalsa J, Dan C, et al. Confronting the emerging epidemic of HCV infection amongst immature injection drug users. Am J Public Health 2014; 104: 816–21.

8. Volkow ND, Frieden TR, Hyde PS, Cha SS. Medication-assisted therapies—tackling the opioid-overdose epidemic. N Engl J Med 2014; 370: 2063–6.

9. Veilleux JC, Colvin PJ, Anderson J, York C, Heinz AJ. A review of opioid dependence treatment: pharmacological and psychosocial interventions to treat opioid habit. Clin Psychol Rev 2010; xxx: 155–66.

10. Loma KP, Rice LS, Connery HS, Weiss RD. Diagnosing and treating opioid dependence. J Fam Pract 2012; 61: 588–97.

11. Bart Grand. Maintenance medication for opiate habit: the foundation of recovery. J Addict Dis 2012; 31: 207–25.

12. World Health System. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: WHO, 2009.

  • Cited Here

13. Correia CJ, Walsh SL, Bigelow GE, Strain EC. Effects associated with double-bullheaded omission of buprenorphine/naloxone over a 98-h flow. Psychopharmacology 2006; 189: 297–306.

14. Amass L, Bickel WK, Higgins ST, Badger GJ. Alternate-mean solar day dosing during buprenorphine treatment of opioid dependence. Life Sci 1994; 54: 1215–28.

15. Tompkins DA, Smith MT, Mintzer MZ, Campbell CM, Strain EC. A double bullheaded, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphine. J Pharmacol Exp Ther 2014; 348: 217–26.

xvi. Sarton E, Teppema 50, Dahan A. Naloxone reversal of opioid-induced respiratory depression with special emphasis on the partial agonist/antagonist buprenorphine. Adv Exp Med Biol 2008; 605: 486–91.

17. Pilgrim JL, McDonough M, Drummer OH. A review of methadone deaths between 2001 and 2005 in Victoria, Australia. Forensic Sci Int 2013; 226: 216–22.

eighteen. McCance-Katz EF, Sullivan LE, Nallani Southward. Drug interactions of clinical importance amongst the opioids, methadone and buprenorphine, and other oftentimes prescribed medications: a review. Am J Addict 2010; nineteen: iv–16.

nineteen. Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction 2013; 108: 1628–37.

20. Diaz A, Pazos A, Florez J, Ayesta FJ, Santana V, Hurle MA. Regulation of mu-opioid receptors, One thousand-protein-coupled receptor kinases and beta-arrestin ii in the rat brain afterwards chronic opioid receptor animosity. Neuroscience 2002; 112: 345–53.

21. Volpe DA, McMahon Tobin GA, et al. Uniform assessment and ranking of opioid mu receptor binding constants for selected opioid drugs. Regul Toxicol Pharmacol 2011; 59: 385–xc.

22. Yuan Y, Zaidi SA, Elbegdorj O, et al. Pattern, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity. J Med Chem 2013; 56: 9156–69.

23. Krupitsky E, Nunes EV, Ling Due west, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011; 377: 1506–13.

24. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. Northward Engl J Med 2003; 349: 949–58.

25. Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone handling for prescription opioid dependence: a two-stage randomized controlled trial. Curvation Gen Psychiatry 2011; 68: 1238–46.

26. Woody GE, Poole SA, Subramaniam G, et al. Extended vs curt-term buprenorphine-naloxone for treatment of opioid-fond youth: a randomized trial. JAMA 2008; 300: 2003–11.

27. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009;(3): CD002209.

  • Cited Here |
  • PubMed

28. Gibson AE, Degenhardt LJ. Mortality related to pharmacotherapies for opioid dependence: a comparative analysis of coronial records. Drug Alcohol Rev 2007; 26: 405–10.

29. Nunes EV, Rothenberg JL, Sullivan MA, Carpenter KM, Kleber HD. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? Am J Drug Alcohol Corruption 2006; 32: 503–17.

  • Cited Here

thirty. Kelty E, Hulse Grand. Exam of bloodshed rates in a retrospective cohort of patients treated with oral or implant naltrexone for problematic opiate use. Addiction 2012; 107: 1817–24.

31. Degenhardt L, Larney S, Kimber J, Farrell M, Hall Westward. Backlog bloodshed among opioid-using patients treated with oral naltrexone in Australia. Drug Alcohol Rev 2014 Oct 10 [Epub ahead of print].

  • Cited Hither

32. Dunn Thou, DeFulio A, Everly JJ, et al. Employment-based reinforcement of adherence to oral naltrexone in unemployed injection drug users: 12-calendar month outcomes. Psychol Addict Behav 2014 Aug 18 [Epub ahead of print].

  • Cited Hither

33. Larney Due south, Gowing 50, Mattick RP, Farrell Grand, Hall W, Degenhardt L. A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence. Drug Booze Rev 2014; 33: 115–28.

34. Ling W, Casadonte P, Bigelow 1000, et al. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial. JAMA 2010; 304: 1576–83.

35. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014; 2: CD002207.

  • Cited Here |
  • PubMed

36. DeFulio A, Everly JJ, Leoutsakos JM, et al. Employment-based reinforcement of adherence to an FDA canonical extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial. Drug Alcohol Depend 2012; 120: 48–54.

37. Everly JJ, DeFulio A, Koffarnus MN, et al. Employment-based reinforcement of adherence to depot naltrexone in unemployed opioid-dependent adults: a randomized controlled trial. Addiction 2011; 106: 1309–eighteen.

38. Thompson G, Kelly E, Christopoulos A, Canals M. Novel GPCR paradigms at the mu-opioid receptor. Br J Pharmacol 2015; 172: 287–96.

39. Williams JT, Ingram SL, Henderson Grand, et al. Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev 2013; 65: 223–54.

twoscore. Birdsong WT, Arttamangkul S, Clark MJ, et al. Increased agonist analogousness at the mu-opioid receptor induced by prolonged agonist exposure. J Neurosci 2013; 33: 4118–27.

41. Sehgal Northward, Manchikanti L, Smith HS. Prescription opioid abuse in chronic hurting: a review of opioid abuse predictors and strategies to curb opioid abuse. Hurting Medico 2012; 15 (three suppl): ES67–92.

  • Cited Here

42. Haerian BS, Haerian MS. OPRM1 rs1799971 polymorphism and opioid dependence: bear witness from a meta-analysis. Pharmacogenomics 2013; fourteen: 813–24.

43. Whistler JL. Examining the role of mu opioid receptor endocytosis in the beneficial and side-effects of prolonged opioid use: from a symposium on new concepts in mu-opioid pharmacology. Drug Booze Depend 2012; 121: 189–204.

44. Grecksch Chiliad, Bartzsch K, Widera A, Becker A, Hollt V, Koch T. Development of tolerance and sensitization to different opioid agonists in rats. Psychopharmacology 2006; 186: 177–84.

  • Cited Here |
  • PubMed

45. Hajj A, Khabbaz L, Laplanche JL, Peoc'h K. Pharmacogenetics of opiates in clinical practice: the visible tip of the iceberg. Pharmacogenomics 2013; fourteen: 575–85.

46. Dennis BB, Bawor Thousand, Thabane L, Sohani Z, Samaan Z. Bear upon of ABCB1 and CYP2B6 genetic polymorphisms on methadone metabolism, dose and treatment response in patients with opioid habit: a systematic review and meta-analysis. PLoS 1 2014; 9: e86114.

47. Dahan A. Opioid-induced respiratory effects: new information on buprenorphine. Palliat Med 2006; 20 suppl 1: s3–eight.

  • Cited Here

48. Zweben JE, Payte JT. Methadone maintenance in the treatment of opioid dependence. A electric current perspective. West J Med 1990; 152: 588–99.

  • Cited Here |
  • PubMed

49. Hser YI, Saxon AJ, Huang D, et al. Treatment memory among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial. Addiction 2014; 109: 79–87.

50. Minozzi Due south, Amato L, Bellisario C, Ferri M, Davoli Yard. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev 2013; 12: CD006318.

  • Cited Here |
  • PubMed

51. Woody 1000, Bruce D, Korthuis PT, et al. HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. J Acquir Immune Defic Syndr 2014; 66: 288–93.

52. Ahmadi J, Ahmadi K, Ohaeri J. Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: a novel report. Eur J Clin Invest 2003; 33: 824–9.

53. Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution handling of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev 2011; (viii): CD004145.

  • Cited Here |
  • PubMed

54. Edelman EJ, Chantarat T, Caffrey S, et al. The bear upon of buprenorphine/naloxone treatment on HIV run a risk behaviors amid HIV-infected, opioid-dependent patients. Drug Booze Depend 2014; 139: 79–85.

55. Otiashvili D, Piralishvili G, Sikharulidze Z, Kamkamidze G, Poole S, Woody GE. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior—outcomes of a randomized trial. Drug Booze Depend 2013; 133: 376–82.

56. Meade CS, Weiss RD, Fitzmaurice GM, et al. HIV risk beliefs in treatment-seeking opioid-dependent youth: results from a NIDA clinical trials network multisite study. J Acquir Immune Defic Syndr 2010; 55: 65–72.

57. Saxon AJ, Ling W, Hillhouse M, et al. Buprenorphine/naloxone and methadone effects on laboratory indices of liver health: a randomized trial. Drug Alcohol Depend 2013; 128: 71–six.

  • Cited Here |
  • PubMed

58. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol 2008; 168: 1099–109.

59. Pouget ER, Hagan H, Des Jarlais DC. Meta-analysis of hepatitis C seroconversion in relation to shared syringes and drug grooming equipment. Addiction 2012; 107: 1057–65.

60. Palmateer N, Hutchinson S, McAllister M, et al. Take chances of transmission associated with sharing drug injecting paraphernalia: analysis of recent hepatitis C virus (HCV) infection using cross-sectional survey information. J Viral Hepat 2014; 21: 25–32.

61. Nolan S, Dias Lima Five, Fairbairn N, et al. The impact of methadone maintenance therapy on hepatitis C incidence amidst illicit drug users. Habit 2014; 109: 2053–9.

62. Tsui JI, Evans JL, Lum PJ, Hahn JA, Page One thousand. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med 2014; 174: 1974–81.

63. Wikner BN, Ohman I, Selden T, Druid H, Brandt L, Kieler H. Opioid-related mortality and filled prescriptions for buprenorphine and methadone. Drug Alcohol Rev 2014; 33: 491–viii.

64. Baumblatt JA, Wiedeman C, Dunn JR, Schaffner Westward, Paulozzi LJ, Jones TF. High-risk use by patients prescribed opioids for pain and its function in overdose deaths. JAMA Intern Med 2014; 174: 796–801.

65. Chou R, Weimer MB, Dana T. Methadone overdose and cardiac arrhythmia potential: findings from a review of the prove for an American Pain Society and College on Problems of Drug Dependence clinical do guideline. J Pain 2014; 15: 338–65.

66. Zlotorzynska M, Milloy MJ, Richardson Fifty, et al. Timing of income assistance payment and overdose patterns at a Canadian supervised injection facility. Int J Drug Policy 2014; 25: 736–9.

67. Darke S. Opioid overdose and the power of erstwhile myths: what we thought we knew, what nosotros do know and why information technology matters. Drug Alcohol Rev 2014; 33: 109–14.

68. Walley AY, Doe-Simkins M, Quinn E, Pierce C, Xuan Z, Ozonoff A. Opioid overdose prevention with intranasal naloxone among people who take methadone. J Subst Abuse Treat 2013; 44: 241–seven.

69. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addiction 1999; 94: 961–72.

70. Zedler B, Xie L, Wang L, et al. Risk factors for serious prescription opioid-related toxicity or overdose among Veterans Health Administration patients. Pain Med 2014; 15: 1911–29.

71. Madadi P, Hildebrandt D, Lauwers AE, Koren K. Characteristics of opioid-users whose death was related to opioid-toxicity: a population-based study in Ontario, Canada. PLoS One 2013; 8: e60600.

72. Centers for Illness Control and Prevention. Community-based opioid overdose prevention programs providing naloxone—U.s., 2010. MMWR Morb Mortal Wkly Rep 2012; 61: 101–v.

  • Cited Here

73. Ritter AJ. Naltrexone in the treatment of heroin dependence: relationship with depression and risk of overdose. Aust Due north Z J Psychiatry 2002; 36: 224–viii.

74. Mitchell MC, Memisoglu A, Silverman BL. Hepatic prophylactic of injectable extended-release naltrexone in patients with chronic hepatitis C and HIV infection. J Stud Alcohol Drugs 2012; 73: 991–vii.

75. McNicholas LF, Holbrook AM, O'Grady KE, et al. Effect of hepatitis C virus status on liver enzymes in opioid-dependent meaning women maintained on opioid-agonist medication. Addiction 2012; 1: 91–7.

76. Bogenschutz MP, Abbott PJ, Kushner R, Tonigan JS, Woody GE. Furnishings of buprenorphine and hepatitis C on liver enzymes in adolescents and immature adults. J Aficionado Med 2010; 4: 211–6.

77. Fung MC, Hsiao-hui Wu H, Kwong K, Hornbuckle K, Muniz Due east. Evaluation of the profile of patients with QTc prolongation in spontaneous agin result reporting over the past three decades—1969–1998. Pharmacoepidemiol Drug Saf 2000; 9: S24.

  • Cited Here |
  • PubMed

78. Pani PP, Trogu E, Maremmani I, Pacini M. QTc interval screening for cardiac risk in methadone treatment of opioid dependence. Cochrane Database Syst Rev 2013; six:CD008939.

  • Cited Here |
  • PubMed

79. Lintzeris Northward, Mitchell TB, Bond AJ, Nestor Fifty, Strang J. Pharmacodynamics of diazepam co-administered with methadone or buprenorphine under high dose atmospheric condition in opioid dependent patients. Drug Alcohol Depend 2007; 91: 187–94.

eighty. Cohier C, Chevillard Fifty, Risede P, Roussel O, Megarbane B. Respiratory effects of buprenorphine/naloxone lonely and in combination with diazepam in naive and tolerant rats. Toxicol Lett 2014; 228: 75–84.

81. Lintzeris N, Mitchell TB, Bond A, Nestor 50, Strang J. Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients. J Clin Psychopharmacol 2006; 26: 274–83.

82. McCance-Katz EF, Moody DE, Prathikanti S, Friedland G, Rainey PM. Rifampin, only not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug Booze Depend 2011; 118: 326–34.

83. McCance-Katz EF, Moody DE, Morse GD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend 2007; 91: 269–78.

84. Saber-Tehrani Equally, Bruce RD, Altice FL. Pharmacokinetic drug interactions and agin consequences betwixt psychotropic medications and pharmacotherapy for the handling of opioid dependence. Am J Drug Alcohol Abuse 2011; 37: 1–eleven.

85. Jones HE, Heil SH, Baewert A, et al. Buprenorphine treatment of opioid-dependent significant women: a comprehensive review. Addiction 2012; ane: 5–27.

86. Gower S, Bartu A, Ilett KF, Doherty D, McLaurin R, Hamilton D. The wellbeing of infants exposed to buprenorphine via breast milk at 4 weeks of age. J Hum Lact 2014; thirty: 217–23.

87. Pritham UA. Breastfeeding promotion for management of neonatal abstinence syndrome. J Obstet Gynecol Neonatal Nurs 2013; 42: 517–26.

88. Gaalema DE, Scott TL, Heil SH, et al. Differences in the contour of neonatal abstinence syndrome signs in methadone-versus buprenorphine-exposed neonates. Addiction 2012; one: 53–62.

89. Salisbury AL, Coyle MG, O'Grady KE, et al. Fetal assessment before and later dosing with buprenorphine or methadone. Addiction 2012; ane: 36–44.

90. Coyle MG, Salisbury AL, Lester BM, et al. Neonatal neurobehavior furnishings post-obit buprenorphine versus methadone exposure. Addiction 2012; i: 63–73.

91. Kaltenbach K, Finnegan LP. Developmental outcome of children born to methadone maintained women: a review of longitudinal studies. Neurobehav Toxicol Teratol 1984; 6: 271–5.

  • Cited Here |
  • PubMed

92. Bell J, Trinh Fifty, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction 2009; 104: 1193–200.

93. Sigmon SC, Bisaga A, Nunes EV, O'Connor PG, Kosten T, Woody G. Opioid detoxification and naltrexone induction strategies: recommendations for clinical practice. Am J Drug Alcohol Corruption 2012; 38: 187–99.

94. Larance B, Lintzeris N, Ali R, et al. The diversion and injection of a buprenorphine-naloxone soluble film conception. Drug Alcohol Depend 2014; 136: 21–7.

95. Schuman-Olivier Z, Connery H, Griffin ML, et al. Clinician beliefs and attitudes almost buprenorphine/naloxone diversion. Am J Addict 2013; 22: 574–80.

96. Pedapati EV, Bateman ST. Toddlers requiring pediatric intensive care unit admission post-obit at-home exposure to buprenorphine/naloxone. Pediatr Crit Care Med 2011; 12: e102–7.

97. Nifty J, Oliver P, Rowse 1000, Mathers N. Residential rehabilitation for drug users: a review of 13 months' intake to a therapeutic community. Fam Pract 2001; 18: 545–eight.

98. Kosten TR, Gorelick DA. The Lexington narcotic farm. Am J Psychiatry 2002; 159: 22.

99. McHugh RK, Murray HW, Hearon BA, et al. Predictors of dropout from psychosocial treatment in opioid-dependent outpatients. Am J Addict 2013; 22: eighteen–22.

100. Warden D, Subramaniam GA, Carmody T, et al. Predictors of attrition with buprenorphine/naloxone treatment in opioid dependent youth. Addict Behav 2012; 37: 1046–53.

101. Mayet S, Farrell K, Ferri Chiliad, Amato 50, Davoli M. Psychosocial treatment for opiate abuse and dependence. Cochrane Database Syst Rev 2005;(1): CD004330.

  • Cited Here |
  • PubMed

102. Masson CL, Barnett PG, Sees KL, et al. Cost and cost-effectiveness of standard methadone maintenance treatment compared to enriched 180-solar day methadone detoxification. Addiction 2004; 99: 718–26.

103. Magura S, Rosenblum A. Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med 2001; 68: 62–74.

  • Cited Here |
  • PubMed

104. Soyka 1000. Opioids and traffic safety—focus on buprenorphine. Pharmacopsychiatry 2014; 47: 7–17.

  • Cited Here |
  • PubMed

105. Rapeli P, Fabritius C, Kalska H, Alho H. Cognitive functioning in opioid-dependent patients treated with buprenorphine, methadone, and other psychoactive medications: stability and correlates. BMC Clin Pharmacol 2011; 11: 13.

106. Garbutt JC, Kranzler Hour, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005; 293: 1617–25.

107. O'Malley SS, Garbutt JC, Gastfriend DR, Dong Q, Kranzler 60 minutes. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before handling. J Clin Psychopharmacol 2007; 27: 507–12.

108. Heinrich CJ, Cummings GR. Adoption and diffusion of testify-based addiction medications in substance abuse treatment. Health Serv Res 2014; 49: 127–52.

109. Lang K, Neil J, Wright J, Dell CA, Berenbaum S, El-Aneed A. Qualitative investigation of barriers to accessing care by people who inject drugs in Saskatoon, Canada: perspectives of service providers. Subst Abuse Treat Prev Policy 2013; viii: 8–35.

  • Cited Here

110. Fiellin DA, O'Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfeld RS. Methadone maintenance in chief care: a randomized controlled trial. JAMA 2001; 286: 1724–31.

111. Roux P, Michel L, Cohen J, et al. Methadone induction in principal intendance (ANRS-Methaville): a stage III randomized intervention trial. BMC Public Health 2012; 12: 488.

  • Cited Here |
  • PubMed

112. Kahan M, Wilson L, Midmer D, Ordean A, Lim H. Short-term outcomes in patients attending a primary care-based addiction shared care program. Tin Fam Doctor 2009; 55: 1108–9.

  • Cited Here |
  • PubMed

113. Debelak K, Morrone WR, O'Grady KE, Jones HE. Buprenorphine + naloxone in the treatment of opioid dependence during pregnancy—initial patient care and outcome data. Am J Aficionado 2013; 22: 252–4.

115. Neumann AM, Blondell RD, Jaanimagi U, et al. A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. J Addict Dis 2013; 32: 68–78.

116. Shi J, Li SX, Zhang XL, et al. Time-dependent neuroendocrine alterations and drug craving during the first month of abstinence in heroin addicts. Am J Drug Alcohol Abuse 2009; 35: 267–72.

117. Li SX, Shi J, Epstein DH, et al. Cyclic alteration in neurobiology during 30 days of forbearance in heroin users. Biol Psychiatry 2009; 65: 905–12.

118. Marsch LA, Bickel WK, Badger GJ, et al. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry 2005; 62: 1157–64.

119. Chartoff EH, Connery HS. It'southward More than heady than mu: crosstalk betwixt mu opioid receptors and glutamatergic transmission in the mesolimbic dopamine system. Front Pharmacol 2014; v: 116.

  • Cited Here

120. Sanders NC, Mancino MJ, Gentry WB, et al. Randomized, placebo-controlled pilot trial of gabapentin during an outpatient, buprenorphine-assisted detoxification procedure. Exp Clin Psychopharmacol 2013; 21: 294–302.

121. Bisaga A, Sullivan MA, Glass A, et al. A placebo-controlled trial of memantine equally an adjunct to injectable extended-release naltrexone for opioid dependence. J Subst Abuse Care for 2014; 46: 546–52.

122. Bisaga A, Sullivan MA, Cheng WY, et al. A placebo controlled trial of memantine every bit an adjunct to oral naltrexone for opioid dependence. Drug Booze Depend 2011; 119: e23–ix.

123. Tabatabai SM, Dashti South, Doosti F, Hosseinzadeh H. Phytotherapy of opioid dependence and withdrawal syndrome: a review. Phytother Res 2014; 28: 811–30.

124. Gao JL, Tu SA, Liu J, et al. An-jun-ning, a traditional herbal formula, attenuates spontaneous withdrawal symptoms via modulation of the dopamine arrangement in morphine-dependent rats. BMC Complement Altern Med 2014; 14: 308.

Keywords:

buprenorphine; medication-assisted treatment; methadone; naltrexone; opioid use disorder

© 2015 President and Fellows of Harvard Higher

betancourtthereves.blogspot.com

Source: https://journals.lww.com/hrpjournal/Fulltext/2015/03000/Medication_Assisted_Treatment_of_Opioid_Use.2.aspx

Post a Comment for "Medication-assisted Treatment of Opioid Use Disorder Review of the Evidence and Future Directions"